EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study

Trial Profile

EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura
  • Focus Adverse reactions
  • Acronyms EXTEND
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top